Tenax Therapeutics Inc (TENX)
3.55
-0.04
(-1.11%)
USD |
NASDAQ |
May 16, 16:00
3.58
+0.03
(+0.85%)
After-Hours: 20:00
Tenax Therapeutics Enterprise Value: -2.340M for May 16, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 16, 2024 | -2.340M |
| May 15, 2024 | -2.261M |
| May 14, 2024 | -2.496M |
| May 13, 2024 | -2.340M |
| May 10, 2024 | -2.271M |
| May 09, 2024 | -2.300M |
| May 08, 2024 | -2.340M |
| May 07, 2024 | -2.379M |
| May 06, 2024 | -2.026M |
| May 03, 2024 | -1.772M |
| May 02, 2024 | -1.870M |
| May 01, 2024 | -1.654M |
| April 30, 2024 | -1.654M |
| April 29, 2024 | -2.105M |
| April 26, 2024 | -2.477M |
| April 25, 2024 | -2.242M |
| April 24, 2024 | -2.32M |
| April 23, 2024 | -2.438M |
| April 22, 2024 | -2.32M |
| April 19, 2024 | -2.183M |
| April 18, 2024 | -2.085M |
| April 17, 2024 | -2.261M |
| April 16, 2024 | -2.222M |
| April 15, 2024 | -2.232M |
| April 12, 2024 | -1.928M |
| Date | Value |
|---|---|
| April 11, 2024 | -1.713M |
| April 10, 2024 | -1.713M |
| April 09, 2024 | -1.615M |
| April 08, 2024 | -1.517M |
| April 05, 2024 | -1.811M |
| April 04, 2024 | -1.811M |
| April 03, 2024 | -1.243M |
| April 02, 2024 | -1.713M |
| April 01, 2024 | -1.811M |
| March 28, 2024 | -0.9885M |
| March 27, 2024 | -1.713M |
| March 26, 2024 | -2.026M |
| March 25, 2024 | -2.046M |
| March 22, 2024 | -1.811M |
| March 21, 2024 | -1.615M |
| March 20, 2024 | -1.752M |
| March 19, 2024 | -2.545M |
| March 18, 2024 | -2.422M |
| March 15, 2024 | -2.669M |
| March 14, 2024 | -2.545M |
| March 13, 2024 | -2.386M |
| March 12, 2024 | -2.227M |
| March 11, 2024 | -2.210M |
| March 08, 2024 | -2.121M |
| March 07, 2024 | -2.174M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-8.239M
Minimum
Jun 16 2023
52.33M
Maximum
Jun 28 2021
7.850M
Average
2.597M
Median
Feb 11 2020
Enterprise Value Benchmarks
| CEL-SCI Corp | 72.33M |
| AIM ImmunoTech Inc | 7.080M |
| IGC Pharma Inc | 36.73M |
| NovaBay Pharmaceuticals Inc | 5.209M |
| Protalix BioTherapeutics Inc | 57.71M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -3.226M |
| Total Expenses (Quarterly) | 3.341M |
| EPS Diluted (Quarterly) | -11.84 |
| Earnings Yield | -964.5% |